OverviewSuggest Edit

NextCure is a biopharmaceutical company focused on discovering and developing next-generation immuno-oncology-based drugs. The Company offers find-io platform which allows to identify proteins that can be targeted with immunomedicines to repair and maintain anti-tumor immunity,  to assess immune pathways in both primary immune cells and established cell lines from immune lineages.
TypePublic
Founded2015
HQBeltsville, US
Websitenextcure.com

Latest Updates

Share Price (Nov 2019)$82.9 (+5%)

Key People/Management at NextCure

Michael Richman

Michael Richman

President, CEO
Steven Cobourn

Steven Cobourn

CFO
Kevin N. Heller

Kevin N. Heller

Chief Medical Officer
Linda Liu

Linda Liu

Senior Vice President
Sebastien Maloveste

Sebastien Maloveste

VP, Business Development
Show more

NextCure Office Locations

NextCure has an office in Beltsville
Beltsville, US (HQ)
9000 Virginia Manor Rd #200
Show all (1)

NextCure Financials and Metrics

NextCure Revenue

USD

Revenue (Q2, 2019)

1.4m

Net income (Q2, 2019)

(8.2m)

EBIT (Q2, 2019)

(9.0m)

Market capitalization (8-Nov-2019)

1.9b

Closing stock price (8-Nov-2019)

82.9

Cash (30-Jun-2019)

192.7m

EV

1.7b
NextCure's current market capitalization is $1.9 b.
Annual
USDFY, 2017FY, 2018

General and administrative expense

2.6m3.4m

R&D expense

13.0m19.8m

Operating expense total

15.5m23.2m

EBIT

(15.5m)(23.2m)
Quarterly
USDQ1, 2019Q2, 2019

Revenue

1.4m1.4m

General and administrative expense

1.7m2.7m

R&D expense

6.5m7.6m

Operating expense total

8.2m10.4m
Annual
USDFY, 2017FY, 2018

Cash

8.4m135.2m

Prepaid Expenses

133.0k152.0k

Current Assets

9.4m135.8m

PP&E

10.0m11.4m
Quarterly
USDQ1, 2019Q2, 2019

Cash

125.5m192.7m

Prepaid Expenses

1.0m3.0m

Current Assets

131.6m196.5m

PP&E

11.8m12.3m
Annual
USDFY, 2017FY, 2018

Net Income

(15.5m)(22.8m)

Depreciation and Amortization

582.0k1.7m

Accounts Payable

767.0k1.3m

Cash From Operating Activities

(12.5m)8.0m
Quarterly
USDQ1, 2019Q2, 2019

Net Income

(6.2m)(14.4m)

Depreciation and Amortization

563.0k1.1m

Accounts Payable

455.0k(493.0k)

Cash From Operating Activities

(7.1m)(17.7m)
USDY, 2019

EV/EBIT

-189.3 x

EV/CFO

-95.9 x

Financial Leverage

1.2 x
Show all financial metrics

NextCure Online and Social Media Presence

Embed Graph

NextCure News and Updates

NextCure Presents Updated Clinical Data from NC318 Phase 1/2 Clinical Trial at the 34th Annual Meeting of Society for Immunotherapy of Cancer (SITC) and Announces Initiation of Phase 2 Portion of the Trial

BELTSVILLE, Md., Nov. 09, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that updated clinical result…

NextCure to Present Clinical Data from NC318 Phase 1/2 Clinical Trial at 34th Annual Meeting of SITC

BELTSVILLE, Md., Oct. 01, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that clinical data from the …

NextCure Reports First Quarter 2019 Financial Results

BELTSVILLE, Md., June 10, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported first quarter 2019 financial …

NextCure Announces Pricing of Initial Public Offering of Common Stock

BELTSVILLE, Md., May 08, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the pricing of its initial pu…

Lilly and NextCure Announce Collaboration to Discover and Develop Novel Immuno-Oncology Medicines

INDIANAPOLIS and BELTSVILLE, Md., Nov. 5, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and NextCure, Inc. today announced a multi-year collaboration focused on the discovery and development of immuno-oncology therapies. The collaboration seeks to discover novel cancer targets...

NextCure Blogs

NextCure Announces Promotion of Timothy Mayer, Ph.D., to Chief Operating Officer

NextCure Announces Promotion of Timothy Mayer, Ph.D., to Chief Operating Officer Content Import Wed, 10/02/2019 - 07:30 NextCure Announces Promotion of Timothy Mayer, Ph.D., to Chief Operating Officer October 2, 2019 at 7:30 AM EDT This release is a backfill f…

NextCure Reports Second Quarter 2019 Financial Results

BELTSVILLE, Md. , Aug. 12, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported second quarter 2019 financial

NextCure Frequently Asked Questions

  • When was NextCure founded?

    NextCure was founded in 2015.

  • Who are NextCure key executives?

    NextCure's key executives are Michael Richman, Steven Cobourn and Kevin N. Heller.

  • Who are NextCure competitors?

    Competitors of NextCure include Akrevia Therapeutics, Karo Pharma and BerGenBio.

  • Where is NextCure headquarters?

    NextCure headquarters is located at 9000 Virginia Manor Rd #200, Beltsville.

  • Where are NextCure offices?

    NextCure has an office in Beltsville.

  • How many offices does NextCure have?

    NextCure has 1 office.